Meagan S Whisenant1, Lorinda A Coombs2, Christina Wilson3, Kathi Mooney4. 1. Department of Research, Cizik School of Nursing, The University of Texas Health Science Center at Houston, Houston, TX, United States; Department of Nursing, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: meagan.whisenant@uth.tmc.edu. 2. University of North Carolina Chapel Hill School of Nursing, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States. 3. University of Utah College of Nursing, Salt Lake City, UT, United States. 4. University of Utah College of Nursing, Salt Lake City, UT, United States; Huntsman Cancer Institute, Salt Lake City, UT, United States.
Abstract
PURPOSE: The purpose of this study was to determine the extent to which women being treated for breast cancer discussed their symptoms during the week prior to a clinic visit. METHOD: Women reported the severity of 11 symptoms (0-10 scale) daily using an automated patient-reported outcomes system. Clinic visits were audio recorded, and symptom discussions were coded. Moderate to severe symptoms reported in the week prior to the visit were compared to the symptoms discussed at the visit. RESULTS: Twenty-six clinic visits of 10 women (mean age, 51.6 years; half had advanced disease) were recorded. In the week prior to their visits, participants provided 183 reports of moderate to severe symptoms. Reported symptoms were discussed at 49.5% of visits, with 36% of discussions initiated by patients. These discussions were more likely to include assessment and normalizing and were less focused on intensifying symptom management. Symptom discussions were more likely with younger women and the time spent discussing symptoms decreased over subsequent visits for all women. CONCLUSIONS: Women who are symptomatic during treatment are not systematically queried about their symptoms, nor are women effectively reporting their symptoms. Attention should be directed at eliciting symptoms from older women; symptoms should be discussed throughout the duration of chemotherapy.
PURPOSE: The purpose of this study was to determine the extent to which women being treated for breast cancer discussed their symptoms during the week prior to a clinic visit. METHOD: Women reported the severity of 11 symptoms (0-10 scale) daily using an automated patient-reported outcomes system. Clinic visits were audio recorded, and symptom discussions were coded. Moderate to severe symptoms reported in the week prior to the visit were compared to the symptoms discussed at the visit. RESULTS: Twenty-six clinic visits of 10 women (mean age, 51.6 years; half had advanced disease) were recorded. In the week prior to their visits, participants provided 183 reports of moderate to severe symptoms. Reported symptoms were discussed at 49.5% of visits, with 36% of discussions initiated by patients. These discussions were more likely to include assessment and normalizing and were less focused on intensifying symptom management. Symptom discussions were more likely with younger women and the time spent discussing symptoms decreased over subsequent visits for all women. CONCLUSIONS: Women who are symptomatic during treatment are not systematically queried about their symptoms, nor are women effectively reporting their symptoms. Attention should be directed at eliciting symptoms from older women; symptoms should be discussed throughout the duration of chemotherapy.
Authors: L S Phillips; W T Branch; C B Cook; J P Doyle; I M El-Kebbi; D L Gallina; C D Miller; D C Ziemer; C S Barnes Journal: Ann Intern Med Date: 2001-11-06 Impact factor: 25.391
Authors: Charles S Cleeland; Xin Shelley Wang; Qiuling Shi; Tito R Mendoza; Sherry L Wright; Madonna D Berry; Donna Malveaux; Pankil K Shah; Ibrahima Gning; Wayne L Hofstetter; Joe B Putnam; Ara A Vaporciyan Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag Journal: JAMA Date: 2017-07-11 Impact factor: 56.272
Authors: Roxanne E Jensen; Nan E Rothrock; Esi M DeWitt; Brennan Spiegel; Carole A Tucker; Heidi M Crane; Christopher B Forrest; Donald L Patrick; Rob Fredericksen; Lisa M Shulman; David Cella; Paul K Crane Journal: Med Care Date: 2015-02 Impact factor: 2.983
Authors: Michael D Brundage; Katherine C Smith; Emily A Little; Elissa T Bantug; Claire F Snyder Journal: Qual Life Res Date: 2015-05-27 Impact factor: 4.147
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Kathi H Mooney; Susan L Beck; Bob Wong; William Dunson; Debra Wujcik; Meagan Whisenant; Gary Donaldson Journal: Cancer Med Date: 2017-01-30 Impact factor: 4.452